Payment & Shipping Terms:
|Quality:||99.5%||Apperance:||White Or White Crystalline Powder|
|Usage:||Muscle To Reduce Fat||MOQ:||10G|
Molecular weight: 296.40300
Exact quality: 296.17800
Appearance and traits: white to light yellow crystal powder
Density: 1.13 g/cm3
Melting point: 155.13 ° C
Boiling point: 453.7oC at 760 mmHg
Flash point: 169oC
Refractive index: 1.572
Storage conditions: Store in original container in a cool dark place.
Steam pressure: 2.02E-08mmHg at 25°C
Signal word: danger
Hazard statement: H319; H360
Warning statement: P201; P305 + P351 + P338; P308 + P313
Packing level: III
Hazard category: 8
Customs code: 2937900090
Dangerous goods transport code: UN 3261 8/PG 2
WGK Germany: 3
Safety instructions: S26-S36/37/39 
The chemical name of exemestane is 1,4-diene-3,17-dione-6-methylenesterrol or 6-methyleneandrost-1,4-diene-3,17-dione , white or off-white crystalline powder; odorless. Soluble in chloroform, soluble in ethyl acetate, acetone, methanol or ethanol, almost insoluble in water. Clinically applicable to postmenopausal women with advanced breast cancer who have progressed after treatment with tamoxifen.
Chinese name: Exemestane
Chinese alias: 1,4-diene-3,17-dione-6-methylene-androstane; exemestane (enterprise); 6-methylene-androst-1,4-diene-3 , 17-dione;
English name: exemestane
English alias: 6-methylenandrosta-1,4-diene-3,17-dione;androsta-1,4-diene-6-methylene-3,17-dione;6-METHYLENEANDROSTA-1,4-DIENE-3,17 -DIONE;Exemestance;6-Methylene-androsta-1,4-diene-3,17-dione;AROMASIN;EXALAMIDE;Exemestan;6-methylenandrost-1,4-diene-3,17-dione;Exemestane;6-Methyleneandrosta -1,4-diene-3,17-dione;
CAS No.: 107868-30-4
Molecular formula: C20H24O2
|Melting point||155.13 ° C|
Exemestane is a steroidal Aromatase Inhibitor (AI) that is most commonly known as Aromasin. In fact, the Aromasin brand name is the only pharmaceutical grade brand of the Exemestane AI due to the tight patent Upjohn has maintained on the product. While tightly controlled by the pharmaceutical giant, Aromasin is available in numerous countries around the globe.
Aromasin was first released on the U.S. market in 2000 after shortly gaining FDA approval a few months prior in 1999. The primary purpose of use as with most AI's would be to combat breast cancer in post-menopausal women. Shortly after, the AI would begin to gain a lot of popularity among anabolic steroid users for its ability to protect against estrogenic related side effects. This action is very similar to the older and more popular AI's in Arimidex and Femara It would also gain a fair amount of popularity in Post Cycle Therapy (PCT) plans among steroid users. It was not the first AI to gain such popularity but would prove to be a little more advantageous for this purpose than most AI's
Aromasin is officially classified as a steroidal suicide Aromatase Inhibitor, and carries the ability to inhibit the aromatase enzyme, which is responsible for the production or conversion of testosterone to estrogen. Aromasin has the ability to block aromatization, which in turn inhibits the production of estrogen, and thereby lowers the body's serum estrogen levels. This will prove useful to breast cancer patients as breast cancer often feeds off the estrogen hormone. It will also prove useful to the anabolic steroid user.